Phase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer

TitlePhase II study of a combination of cyclophosphamide, adriamycin and cisplatin in advanced fallopian tube carcinoma. An EORTC gynecological cancer group study. European Organization for Research and Treatment of Cancer
Publication TypeJournal Article
Year of Publication2001
AuthorsWagenaar, HC, Pecorelli, S, Vergote, IB, Curran, D, Wagener, DJ, Kobierska, A, Bolis, G, Bokkel-Huinink, WT, Lacave, AJ, Madronal, C, Forn, M, de Oliveira, CF, Mangioni, C, Nooij, MA, Goupil, A, Kerbrat, P, Marth, CH, Tumolo, S, Herben, MG, Zanaboni, F, Vermorken, JB
JournalEur J Gynaecol Oncol
Volume22
Pagination187-93
KeywordsAdenocarcinoma, administration & dosage, administration & dosage Antineoplastic Agents, administration & dosage Antineoplastic Combined Chemotherapy Protocols, administration & dosage Cyclophosphamide/administration & dosage Doxorubicin/administration & dosage Drug, adverse effects, Alkylating, Antineoplastic, drug therapy, pathology Aged Antibiotics, therapeutic use Cisplatin
Abstract

OBJECTIVE: To investigate the clinical activity and toxicity of a combination chemotherapy consisting of cyclophosphamide (C), adriamycin (A) and cisplatin (P) for patients with primary adenocarcinoma of the Fallopian tube having FIGO stage III-IV disease. METHODS: The CAP-regimen consisted of cyclophosphamide 600 mg/m2, adriamycin 45 mg/m2, and cisplatin 50 mg/m2 administered intravenously on day one every 28 days. RESULTS: Twenty-four eligible patients with histologically-confirmed Fallopian tube adenocarcinoma were entered in the trial. Fourteen patients had FIGO stage III, and ten had stage IV disease. The median number of CAP cycles was six. Ten patients had a complete and six had a partial response (response rate: 67%, 95% confidence limits: 45-84%). WHO grade III-IV side-effects included haematological toxicity, nausea/vomiting and alopecia. Furthermore, mild signs of cisplatin-related peripheral neurotoxicity were observed. At a median follow-up of 40 months, nine patients were alive and 15 had died due to malignant disease. The median time to progression was 13 months for all patients. The median overall survival was 24 months and the 1-, 3- and 5-year survival and their 95% confidence limits were 73% (54-92%), 25% (4-46%) and 19% (0-38%), respectively. CONCLUSION: The present data confirm the therapeutic activity of the CAP-regimen in primary Fallopian tube adenocarcinoma. The response rate is moderate and the toxicity profile is acceptable.